Cargando…
Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study
BACKGROUND: In our previous study, colorectal cancer (CRC) patients with active Mycobacterium tuberculosis (MTB) tolerated concurrent anti-cancer chemotherapy (anti-CCT) and anti-MTB chemotherapy. In this study, we retrospectively confirmed the efficacy and safety of concurrent chemotherapy in a gre...
Autores principales: | Hirashima, Tomonori, Tamura, Yoshitaka, Han, Yuki, Hashimoto, Shoji, Tanaka, Ayako, Shiroyama, Takayuki, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Akada, Shinobu, Fujishima, Makoto, Kadota, Yoshihisa, Sakata, Kazuya, Nishitani, Akiko, Miyazaki, Satoru, Nagai, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186130/ https://www.ncbi.nlm.nih.gov/pubmed/30314434 http://dx.doi.org/10.1186/s12885-018-4889-1 |
Ejemplares similares
-
Transbronchial Cryobiopsy for Miliary Tuberculosis Mimicking Hypersensitivity Pneumonitis
por: Nasu, Shingo, et al.
Publicado: (2020) -
Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study
por: Hirashima, Tomonori, et al.
Publicado: (2014) -
Successful retreatment with osimertinib after osimertinib-induced acute pulmonary embolism in a patient with lung adenocarcinoma: A case report
por: Shiroyama, Takayuki, et al.
Publicado: (2016) -
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017) -
A case of successful concurrent anti-cancer treatment in a patient who developed follicular lymphoma during treatment with afatinib for advanced lung adenocarcinoma
por: Masuhiro, Kentaro, et al.
Publicado: (2019)